Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

2.

Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.

Anaissie EJ, Coleman EA, Goodwin JA, Kennedy RL, Lockhart KD, Stewart CB, Coon SK, Bailey C, Barlogie B.

Cancer. 2012 Jan 15;118(2):549-57. doi: 10.1002/cncr.26302. Epub 2011 Jun 30.

3.

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group.

Leukemia. 2008 Feb;22(2):414-23. Epub 2007 Dec 20. Review.

PMID:
18094721
4.

Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.

Wu SY, Yeh YM, Chen YP, Su WC, Chen TY.

Ann Hematol. 2012 Nov;91(11):1773-8. doi: 10.1007/s00277-012-1506-2. Epub 2012 Jun 17.

PMID:
22706703
5.

Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.

Cini M, Zamagni E, Valdré L, Palareti G, Patriarca F, Tacchetti P, Legnani C, Catalano L, Masini L, Tosi P, Gozzetti A, Cavo M.

Eur J Haematol. 2010 Jun;84(6):484-92. doi: 10.1111/j.1600-0609.2010.01434.x. Epub 2010 Feb 23.

PMID:
20192986
6.

Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.

Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M.

Semin Thromb Hemost. 2011 Apr;37(3):209-19. doi: 10.1055/s-0031-1273085. Epub 2011 Mar 31.

PMID:
21455855
7.

Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.

Alexander M, Teoh KC, Lingaratnam S, Kirsa S, Mellor JD.

Asia Pac J Clin Oncol. 2013 Jun;9(2):169-75. doi: 10.1111/ajco.12013. Epub 2012 Sep 24.

PMID:
22998589
8.

Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence.

Alexander M, Kirsa S, Mellor JD.

Asia Pac J Clin Oncol. 2012 Dec;8(4):319-24. doi: 10.1111/j.1743-7563.2011.01511.x. Epub 2012 Apr 23. Review.

PMID:
22897571
9.

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A.

Blood. 2012 Jan 26;119(4):933-9; quiz 1093. doi: 10.1182/blood-2011-03-344333. Epub 2011 Aug 11.

10.

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.

Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, Karam MA, Faiman B, Jawde RA, Andresen S, Zeldis J, Hussein MA.

Mayo Clin Proc. 2005 Dec;80(12):1568-74.

PMID:
16342649
11.

Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.

Isoda A, Sato N, Miyazawa Y, Matsumoto Y, Koumoto M, Ookawa M, Sawamura M, Matsumoto M.

Int J Hematol. 2015 Sep;102(3):271-7. doi: 10.1007/s12185-015-1838-5. Epub 2015 Jul 16.

PMID:
26177588
12.

Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.

Carrier M, Le Gal G, Tay J, Wu C, Lee AY.

J Thromb Haemost. 2011 Apr;9(4):653-63. doi: 10.1111/j.1538-7836.2011.04215.x. Review.

13.

Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.

Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT.

Thromb Res. 2009 Mar;123(5):679-86. doi: 10.1016/j.thromres.2008.09.008. Epub 2008 Nov 6. Review.

PMID:
18992924
14.

Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.

Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M.

J Clin Oncol. 2011 Mar 10;29(8):986-93. doi: 10.1200/JCO.2010.31.6844. Epub 2011 Jan 31.

15.

[Thromboprophylaxis in patients with multiply myeloma who receives chemotherapy with thalidomide].

Novosad OI, Kriachok IA, Kadnikova TV, Filonenko KS, Tytorenko IB, Martynchyk AV, Aleksyk OM, Gusachenko IuO, Filonenko IA.

Lik Sprava. 2011 Apr-Jun;(3-4):44-50. Review. Ukrainian.

PMID:
22416363
16.

Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism.

Miller KC, Padmanabhan S, Dimicelli L, Depaolo D, Landrigan B, Yu J, Doran V, Marshal P, Chanan-Khan A.

Leuk Lymphoma. 2006 Nov;47(11):2339-43.

PMID:
17107907
17.

Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.

Thaler J, Ay C, Pabinger I.

Thromb Haemost. 2012 Dec;108(6):1042-8. doi: 10.1160/TH12-04-0241. Epub 2012 Jul 26. Review.

PMID:
22836491
19.

Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.

Almasi M, Sevcikova S, Slaby O, Kaisarova P, Maisnar V, Penka M, Pika T, Pour L, Radocha J, Scudla V, Svachova H, Hajek R.

Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):414-20. doi: 10.1016/j.clml.2011.03.024. Epub 2011 May 10.

PMID:
21859556
20.

Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.

Zangari M, Fink L, Zhan F, Tricot G.

Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):228-36. doi: 10.1016/j.clml.2011.03.006. Epub 2011 Apr 8. Review.

PMID:
21575928
Items per page

Supplemental Content

Write to the Help Desk